nivolumab — drug repurposing hypotheses

CROSS-DOMAIN PATTERN

Same drug, multiple disease domains

nivolumab appears in hypotheses across 4 disease domains: ALS, Glioblastoma, Inflammatory bowel disease, Pancreatic cancer. Shared mediators that recur across at least two of those domains: PD-1.

Aggregated from the catalog. Biological interpretation of any multi-indication mechanism would require independent validation — this is a structural observation only.

ALL HYPOTHESES

Repurposing candidates for nivolumab

ALS 3

Mediator	Outcome	Score	Tier	Lit. status	Trial
PD-1	ALS	0.208	Mid	partial evidence	none
PD-1	ALS disease progression	0.208	Mid	novel signal	none
PD-1	unfavorable prognosis	0.208	Mid	reproduces known	none

Glioblastoma 1

Mediator	Outcome	Score	Tier	Lit. status	Trial
PD-1	glioblastoma growth	0.208	Mid	novel signal	none

Inflammatory bowel disease 1

Mediator	Outcome	Score	Tier	Lit. status	Trial
PD-1	PD-1 inhibitor-associated colitis	0.208	Mid	novel signal	none

Pancreatic cancer 4

Mediator	Outcome	Score	Tier	Lit. status	Trial
PD-1	pancreatic cancer	0.208	Mid	reproduces known	active
PD-1	prognosis	0.208	Mid	reproduces known	active
PD-1	lymph node metastasis	0.208	Mid	reproduces known	active
PD-1	advanced T stage	0.208	Mid	novel signal	active

← All drugs